Výsledky vyhledávání - "Nicole Hirsh"

Figure S2 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

Autor: Corey Speers, Reshma Jagsi, Lori J. Pierce, Shyam Nyati, Meilan Liu, Cassandra L. Ritter, Nicole Hirsh, Amanda Zhang, Dafydd G. Thomas, Eric Olsen, Meleah Cameron, Kari Wilder-Romans, Benjamin C. Chandler, Leah Moubadder, Andrea M. Pesch, Anna R. Michmerhuizen

Higher doses of olaparib are sufficient to inhibit PAR formation in BRCA1-mutant SUM-149 cells. At higher concentrations of olaparib (1μM), combination treatment of PARP1 inhibition and radiation decreases PAR in a comparable manner to lower doses o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::623d55d5dd22fc6feaa49169a3f1f0b6
https://doi.org/10.1158/1535-7163.22518895

Zobrazit plný text záznamu

Figure S3 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

Ki67 and p16 levels are decreased in tumors from animals treated with radiation and combination PARP-inhibitor and radiation. SUM-190 xenograft tumors that were harvested from mice at the completion of the long-term in vivo study. Protein expression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057703d4bde74df38c00e6668f4ad8bf
https://doi.org/10.1158/1535-7163.22518892

Zobrazit plný text záznamu

Figure S4 from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

Total PARP1 levels do not change with treatment but PAR levels are decreased by PARPi. Total levels of PARP1 were assessed in tumors from mice treated with olaparib. Olaparib treatment did not affect PARP1 protein expression by IHC in olaparib-alone,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::824f34ca3b79b528a88bfc2ddafacc24
https://doi.org/10.1158/1535-7163.22518886

Zobrazit plný text záznamu

Data from PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

Sustained locoregional control of disease is a significant issue in patients with inflammatory breast cancer (IBC), with local control rates of 80% or less at 5 years. Given the unsatisfactory outcomes for these patients, there is a clear need for in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ab813eb94ed0666f01ed7b66b76c82
https://doi.org/10.1158/1535-7163.c.6542167

Zobrazit plný text záznamu

Abstract 1727: Cytoplasmic EZH2 and the DLC1 tumor suppressor are regulated by the CRM1 nuclear export protein and by specific complex formation between mutant KRAS and RAN-GAP

Autor: Brajendra Tripathi, Nicole Hirsh, David Hansen, Xiaolan Qian, Dunrui Wang, Marian E. Durkin, Ashley Lim, Alex G. Papageorge, Suresh S. Ramalingham, Adam I. Marcus, Douglas R. Lowy

Publikováno v: Cancer Research. 83:1727-1727

The DLC1 tumor suppressor gene encodes a cytoplasmic RHO-GAP protein whose expression is frequently decreased in many cancer types, especially lung cancer. We have identified several cancer-associated post-translational modifications in the DLC1 prot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c36e2284020d3850d059e8c4142e1ff3
https://doi.org/10.1158/1538-7445.am2023-1727

Zobrazit plný text záznamu

Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein

Autor: Brajendra K. Tripathi, Nicole Hirsh, Xiaolan Qian, Dunrui Wang, Marian E. Durkin, Fernando J. de Miguel, Katerina Politi, James H. Doroshow, Douglas R. Lowy

Publikováno v: Cancer Research. 82:5848-5848

Mutant KRAS is found in >30% of lung adenocarcinomas, and tumors with mutant KRAS usually have poor outcomes with current therapies. The rationale for the new treatment approach described here for tumors with mutant KRAS arises from the critical anti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59447d7f847360c3a2d04b5852d58b65
https://doi.org/10.1158/1538-7445.am2022-5848

Zobrazit plný text záznamu

Abstract 216: Expression of DNA damage response proteins modifies the efficacy of CDK4/6 inhibitor-mediated radiosensitization in breast cancer models

Autor: Kassidy M. Jungles, Andrea M. Pesch, Nicole Hirsh, Anna R. Michmerhuizen, Kari Wilder-Romans, Benjamin C. Chandler, Meilan Liu, Lynn Lerner, Lori J. Pierce, James M. Rae, Corey W. Speers

Publikováno v: Cancer Research. 82:216-216

Purpose: CDK4/6 inhibitors (CDK4/6i) are standard of care for the treatment of locally advanced and metastatic estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer (BC). CDK4/6 inhibition + radiation therapy (RT) is synergistic in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c28d7093ef36f6394ca5d554a29cc39
https://doi.org/10.1158/1538-7445.am2022-216

Zobrazit plný text záznamu

CDK4/6 Inhibition and Radiation as a Treatment Strategy to Improve Local Disease Control in Breast Cancers With Poor Prognoses

Autor: James M. Rae, Corey Speers, Anna R. Michmerhuizen, Daniel F. Hayes, Nicole Hirsh, Kari Wilder-Romans, Andrea M. Pesch, Meilan Liu, Lori J. Pierce, L Lerner, Erin F. Cobain, B. Chandler

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 111:S55-S56

Purpose/objective(s) Locoregional control remains an issue in women with multi-node positive estrogen receptor-positive (ER+) breast cancer and many women with triple-negative breast cancer (TNBC). There is growing evidence that CDK4/6 inhibition (CD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e712161ac7e70e09db32dc66fde0406
https://doi.org/10.1016/j.ijrobp.2021.07.143

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání